NEXGEL, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
NXGL Nasdaq 3850 nexgel.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NEXGEL, Inc.

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th - Jun 4th, 2026 7:00 am
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration - May 19th, 2026 7:00 am
Nexgel (NXGL) Q1 2026 Earnings Transcript - May 15th, 2026 10:54 am
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical - May 13th, 2026 6:30 am
NEXGEL To Report First Quarter 2026 Financial Results on May 15th - May 12th, 2026 8:27 am
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors - May 6th, 2026 7:00 am
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Apr 27th, 2026 7:00 am
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Apr 21st, 2026 7:00 am
Celularity Announces Closing of Transaction with NexGel - Apr 21st, 2026 6:30 am
NEXGEL, Inc. Q4 2025 Earnings Call Summary - Apr 21st, 2026 6:30 am
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET - Apr 17th, 2026 1:37 pm
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - Apr 15th, 2026 2:12 pm
NexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... - Apr 8th, 2026 7:00 pm
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction - Apr 8th, 2026 2:05 pm
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - Mar 31st, 2026 2:12 pm
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st - Mar 25th, 2026 7:00 am
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - Mar 12th, 2026 6:45 am
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - Mar 12th, 2026 6:30 am
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - Mar 10th, 2026 6:45 am
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence - Feb 10th, 2026 7:00 am